poisar

Stocks · News reference

QNRX shares are trading higher after the company announced interim Phase 2/3 results showing QRX003 met the primary and key secondary endpoints with statistical significance, along with itch reduction and no serious adverse events.

BenzingaAug 28, 2026, 5:59 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 28, 2026, 5:59 PM
Checked
Aug 28, 2026, 5:59 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARAug 28, 2026, 2:31 PMSEC EDGAR

    8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)

    Filed: 2026-08-28 AccNo: 0001104659-26-102917 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    Read original at edgar